May 14, 2025

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Brad Sorensen
312-265-9574
bsorensen@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

Ensysce Biosciences (ENSC-NASDAQ)

ENSC: Pivotal Year Off to Good Start

ENSC is a clinical stage pharmaceutical company dedicated to bringing a novel opioid to the market that resists the addictive properties that have plagued society.

OUTLOOK

Ensysce Biosciences is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid.

The company released 1Q2025 financial data and reminded investors that 2025 is looking to be a potentially pivotal year for ENSC.

Current Price (05/13/25)	$2.07
Valuation	**$18.45**

SUMMARY DATA

52-Week High	**$11.08**
52-Week Low	**$1.66**
One-Year Return (%)	**-75.14**
Beta	**1.09**
Average Daily Volume (sh)	**4,891,789**
Shares Outstanding (mil)	**2**
Market Capitalization ($mil)	**$5**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**6**
Insider Ownership (%)	**8**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2023 Estimate	**N/A**
P/E using 2024 Estimate	**N/A**
Zacks Rank	**N/A**

Risk Level	**High**
Type of Stock	**Small-Blend**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(in millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	0.6A	0.2A	0.3A	1.4A	2.5A
2023	0.8A	0.5A	0.4A	0.5A	2.2A
2024	0.3A	0.2A	3.4A	1.3A	5.2A
2025	1.3A	1.3E	1.4E	1.4E	5.4E

Earnings per share

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2022	-0.06A	-0.24A	-5.13A	-2.55A	-1.48A
2023	-2.08A	-0.98A	-0.87A	-1.13A	-5.06A
2024	-0.55A	-0.22A	0.07A	-2.90A	-11.45A
2025	-1.39A	-0.75E	-0.72E	-0.70E	-3.56E

*quarters don't add to yearly total due to reverse stock split and share issuance.

© Copyright 2025, Zacks Investment Research. All Rights Reserved.

Update

Ensysce Biosciences (ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that have plagued the American public.

The company recently released its 1Q2025 financial results that showed revenue of $1.3 million from a Federal Grant, which is currently scheduled to run through 2027. Additionally, with the exercise of some warrants, the company's cash balance, which was $3.1 million at the end of the quarter, added an additional $2.2 million, minus fees and expenses related to the exercise.

This is looking to be a pivotal year for ENSC, with the company's lead product, PF614, which is a potential "next generation" analgesic to treat pain relief and is abuse resistant, potentially undergoing a Phase 3 trial by the middle of 2025. Additionally, the company's PF614-MPAR product is progressing to Part 2 of a three-part study, which will be used to perfect the final drug product to more into commercialization.

As part of that testing, earlier in the year, the company released data on its PF614-MPAR compound, which is designed to treat pain and provided overdose protection. In the study, subjects were received up to five 100 mg doses of the overdose-protected PF614-MPAR versus the unprotected PF614. The data showed that the maximum amount of oxycodone released from PF614-MPAR, when three or more doses were taken at one time was reduced compared to that released following the consumption of same amount of PF614 alone, evidence of overdose protection. When five doses of PF614-MPAR were administered, overdose protection was appropriately greater than that observed from three dose units. Additionally, safety data from the trial showed that there were no unexpected adverse events from either PF614 or PF614-MPAR.

This data further confirms our belief that ENSC is developing a potentially game-changing treatment that could change patients' lives by providing much-needed pain relief, while greatly reducing the risk of abuse. Company management noted that they will use this data in discussions with the FDA regarding the full development plan for this compound.

Illustrating the belief in this treatment, in 2024, the company announced that it has received a $14 million grant from the National Institute of Health (NIH) for the continued clinical development of PF614-MPAR—the company's abuse-deterrent opioid with overdose protection. The award will be paid over three years and, according to the company, allow for the completion of crucial clinical trials. This award creates multiple positive impacts for the company. First, the money from the grant will help fund operations and further clinical testing, while allowing the company to limit future potential dilution to shareholders. Additionally, the award represents, in our view, another positive vote from a respected medical organization that has seen the initial data and believes in the potential benefits of this treatment.

We aren't going to rehash recent reports that have outlined the positive test results for PF614 and PF614-MPAR. But, as a reminder, these tests have shown that PF614 can provide the much-needed pain relief that is currently available through the highly abused oxycodone, while having abuse resistant properties and lasting longer. Additionally, an important reminder that PF-614-MPAR received an FDA grant of Breakthrough Therapy designation, which allows ENSC the opportunity to accelerate clinical programs and commercialization plans. The grant, which has

been applied to fewer than 300 drugs historically, illustrates the importance and urgency that these solutions are needed. We are again reiterating our belief that the treatments being developed by Ensysce will be game changers in the pain relief market and again suggest that investors take a strong look at ENSC.

PF614-MPAR has been shown in testing to have the potential to provide much needed pain relief to patients and provides protections against taking too many pills, which often leads to debilitating addiction. The technology involved causes the drug to become inactive when dosing requirements are exceeded—greatly diminishing the "incentive" patients may have to take more than the prescribed dose.

Ensysce Biosciences continues to be one of the companies that we cover that we believe most of America would hope is successful and one we are becoming more convinced will achieve its goals. The opioid crisis remains a plague on the American public and is destroying families and entire communities. The National Institute on Drug Abuse reported more than 107,000 overdose deaths in 2022—and that doesn't count the millions of family members and friends impacted by those deaths. Ensysce has extremely promising technology in the form of PF614 and PF614-MPAR that are abuse resistant, while still providing the much-needed pain relief that many Americans need with a longer lasting dose than its bioequivalent OxyContin.

We have written for some time how important the work ENSC is doing is and continue to believe that. We also believe that investors who invest in such important work have the potential to be rewarded quite well as these solutions to a problem plaguing thousands of families come to fruition. We encourage investors to take a look at ENSC and consider the stock before the anticipated positive testing results come in.


PROJECTED INCOME STATEMENT & BALANCE SHEET

Ensysce Biosciences

Income Statement and Balance Sheet

		1Q/2024A	2Q/2024A	3Q/2024A	4Q/2024A	1Q/2025A	2Q/2025E	3Q/2025E	4Q/2025E	12/2026E
Income										
	Federal Grants	305,722	181,797	3,418,853	1,303,659	1,319,772	1,346,167	1,373,091	1,400,553	0
	Sales	0	0	0	0	0	0	0	0	10,000,000
Operating Expenses										
	COGS	0	0	0	0	0	0	0	0	(1,000,000)
	R&D	(778,904)	(947,229)	(1,690,674)	(3,802,630)	(1,885,528)	(1,923,239)	(1,961,703)	(2,000,937)	(1,979,804)
Other	Sales/Marketing	0	0	0	0	0	0	0	0	(1,000,000)
	Admin/general/other	(1,369,782)	(1,190,010)	(1,083,433)	(1,077,505)	(1,379,817)	(1,407,413)	(1,435,562)	(1,464,273)	(1,448,808)
	Interest	(1,248,065)	0	0	0	(3,856)	(3,933)	(4,012)	(4,092)	(15,424)
	Adjustments to net income	(25,534)	(12,351)	17,023	12,054	0	0	0	0	0
Gain/loss		(3,116,563)	(1,967,793)	661,769	(3,564,422)	(1,945,573)	(1,984,484)	(2,024,174)	(2,064,658)	6,571,388
Loss attributable to noncontrolling		(74)	0	0	0	0	0	0	0	0
Deemed div. rel.to warrants		290	0	0	0	0	0	0	0	0
Net Loss Attr. to Common S/H		(3,116,779)	(1,967,793)	661,769	(3,564,422)	(1,945,573)	(1,984,484)	(2,024,174)	(2,064,658)	6,571,388
Shares		5,694,466	8,817,316	9,890,390	1,229,111	1,401,144	2,661,896	2,794,991	2,934,740	3,081,477
Per share		($0.55)	($0.22)	$0.07	($2.90)	($1.39)	($0.75)	($0.72)	($0.70)	$2.13
Assets										
	Cash	3,404,349	1,043,231	4,153,592	3,502,077	3,052,491	2,899,866	2,754,873	2,617,129	3,205,116
	Other	1,669,841	1,752,389	5,231,132	2,095,155	1,559,383	1,590,571	1,622,382	1,654,830	1,637,352
Total Assets		5,074,190	2,795,620	9,384,724	5,597,232	4,611,874	4,490,437	4,377,255	4,271,959	4,842,468
Liabilities										
	Accounts Payable	981,720	481,971	1,967,573	1,357,079	615,295	627,601	640,153	652,956	633,754
	Other liabilities	654,408	824,649	834,211	850,118	1,145,881	1,168,799	1,192,175	1,216,018	1,180,257
Long-term liabilities		17,433	9,615	3,213	10,096	130,180	132,784	135,439	138,148	134,085
Total liabilities		1,653,561	1,316,235	2,804,997	2,217,293	1,891,356	1,929,183	1,967,767	2,007,122	1,948,097
Shareholder deficit/surplus		3,420,629	1,479,385	6,579,727	3,379,939	2,720,518	732,713	827,224	927,618	2,894,371
Total liabilities and shareholder equ		5,074,190	2,795,620	9,384,724	5,597,232	4,611,874	2,661,896	2,794,991	2,934,740	4,842,468

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Brad Sorensen, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.